Ana is a molecular biologist with a passion for communication and discovery. As a science writer, her goal is to provide readers, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.
Second-line maintenance therapy with the experimental vaccine galinpepimut-S (GPS) significantly prolongs the life of patients with acute myeloid leukemia (AML) who are on their second remission of the disease, according ... Read more
An early trial testing the investigational radioimmunotherapy Actimab-A plus chemotherapy in people with relapsing or refractory acute myeloid leukemia (AML) has begun dosing a final group of patients, Actinium Pharmaceuticals announced. Preliminary ... Read more
First-line treatment with a combination of Venclexta (venetoclax) and a low dose of cytarabine failed to significantly extend the survival of people with acute myeloid leukemia (AML) who were ineligible ... Read more
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Precigen‘s PRGN-3006, an investigational CAR T-cell therapy with the potential to provide faster, more durable, and safer ... Read more
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to AB Science‘s investigational agent AB8939, a small molecule designed to treat acute myeloid leukemia (AML), the company announced. This ... Read more